Preferred Label : Ustekinumab;

NCIt synonyms : Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit beta (IL-12B, CLMF p40, NKSF2)) (Human Monoclonal CNTO 1275 gamma1-chain), Disulfide with Human Monoclonal CNTO 1275 kappa-chain, Dimer;

NCIt definition : An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to their interleukin receptors. This inhibits IL-12- and IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent graft versus host disease (GVHD). IL-12 and IL-23, cytokines that play a key role in the regulation of the immune system, are upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.;

UNII : FU77B4U5Z0;

CAS number : 815610-63-0;

Drug name : Stelara;

Molecule name : CNTO1275; CNTO 1275;

Details


Main resources

You can consult :


https://assurance-maladie.ameli.fr/etudes-et-donnees/2024-vedolizumab-ustekinumab-anti-tnf-grossesse-mici
2024
France
scientific and technical information
safety
TNF Gene
Ustekinumab
inflammatory bowel disease, nos
tumor necrosis factor
Institutional Review Board Independent Ethics Committee Notification of Safety Information Documentation
Physically Feel in Bad Condition
tumor necrosis factors
Safety Report
Clinical Trial Notification of Safety or Other Trial Information Documentation
chronic disease, nos
Vedolizumab
research report
vedolizumab
disease
Tumor Necrosis Factor
anti-TNF
Ustekinumab
Chronic Disease
Pregnant People
inflammatory bowel diseases
vedolizumab
pregnancy, nos
albumin/globulin ratio
chronic disease
Gravida

---
Nous contacter.
08/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.